More information: Kai Chen et al, mLumiOpto Is a Mitochondrial-Targeted Gene Therapy for Treating Cancer, Cancer Research (2024). DOI: 10.1158/0008-5472.CAN-24-0984 ...

is in Phase III trials in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based ...

Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the way for improved immunotherapies.

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that ...

Chameleon Biosciences, a gene therapy company based in Berkeley ... Niemann-Pick disease type C (NPC), mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), and severe hemophilia A.

How is mitochondrial gene expression monitored and regulated within the cell? Surprisingly, this very simple and basic question is very poorly understood in general let alone how it occurs under ...

Mitochondrial gene products interact with those encoded in nuclear genes, and sometimes with the nuclear genome itself. Because the mitochondrial genome mutates faster than the nuclear genome, it ...

the company’s investigational gene therapy for Leber Hereditary Optic Neuropathy (LHON) due to a mutated ND4 mitochondrial gene. The patients had all participated in the phase III trials RESCUE and ...